5.19
price down icon0.67%   -0.04
after-market アフターアワーズ: 5.15 -0.04 -0.77%
loading
前日終値:
$5.23
開ける:
$5.23
24時間の取引高:
1.89M
Relative Volume:
1.34
時価総額:
$350.62M
収益:
$380.79M
当期純損益:
$49.27M
株価収益率:
-4.1855
EPS:
-1.24
ネットキャッシュフロー:
$10.68M
1週間 パフォーマンス:
+3.49%
1か月 パフォーマンス:
+11.48%
6か月 パフォーマンス:
+188.61%
1年 パフォーマンス:
-58.90%
1日の値動き範囲:
Value
$4.98
$5.416
1週間の範囲:
Value
$4.5701
$5.88
52週間の値動き範囲:
Value
$1.575
$19.95

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name
名前
Amylyx Pharmaceuticals Inc
Name
セクター
Healthcare (1196)
Name
電話
617-683-0917
Name
住所
43 THORNDIKE STREET, CAMBRIDGE
Name
職員
384
Name
Twitter
Name
次回の収益日
2024-08-08
Name
最新のSEC提出書
Name
AMLX's Discussions on Twitter

AMLX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AMLX 5.19 350.62M 380.79M 49.27M 10.68M -1.24
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-01-03 開始されました Robert W. Baird Outperform
2023-12-12 開始されました Deutsche Bank Buy
2023-07-24 アップグレード Goldman Neutral → Buy
2023-03-31 開始されました Mizuho Buy
2023-01-05 開始されました BofA Securities Buy
2022-05-25 開始されました Citigroup Buy
2022-04-01 ダウングレード Goldman Buy → Neutral
すべてを表示

Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース

pulisher
08:29 AM

Goldman Sachs reiterates Neutral on Amylyx stock, target unchanged amid PBH market uncertainties - Investing.com

08:29 AM
pulisher
Nov 19, 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Baird R W - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Baird Upgrades Amylyx Pharmaceuticals (AMLX) - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise - MSN

Nov 18, 2024
pulisher
Nov 18, 2024

Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Robert W. Baird to Outperform Rating - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat

Nov 15, 2024
pulisher
Nov 11, 2024

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024
pulisher
Nov 09, 2024

Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $12.00 Price Target at HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Amylyx Pharmaceuticals Q3 2024 Financial Highlights - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Amylyx Pharmaceuticals Inc. (AMLX) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Bakersfield Californian

Nov 07, 2024
pulisher
Nov 07, 2024

Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St

Nov 04, 2024
pulisher
Nov 04, 2024

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan

Nov 04, 2024
pulisher
Nov 03, 2024

abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Nov 01, 2024
pulisher
Oct 30, 2024

Levi & Korsinsky Reminds Amylyx Investors of the Pending Class A - GuruFocus.com

Oct 30, 2024
pulisher
Oct 28, 2024

Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 21.1% - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc - Yahoo Finance

Oct 25, 2024
pulisher
Oct 25, 2024

Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharma - GuruFocus.com

Oct 25, 2024
pulisher
Oct 24, 2024

Amylyx upgraded to buy by BofA on hypoglycemia drug potential - MSN

Oct 24, 2024
pulisher
Oct 23, 2024

BofA upgrades Amylyx stock to Buy rating By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

BofA upgrades Amylyx stock to Buy rating - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Buy by Bank of America - MarketBeat

Oct 23, 2024
pulisher
Oct 22, 2024

Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus.com

Oct 22, 2024
pulisher
Oct 21, 2024

October 2024's US Penny Stocks Poised For Growth - Simply Wall St

Oct 21, 2024
pulisher
Oct 19, 2024

Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial - MSN

Oct 19, 2024
pulisher
Oct 19, 2024

Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments - Insider Monkey

Oct 19, 2024
pulisher
Oct 18, 2024

Why Amylyx Pharmaceuticals Stock Was So Healthy This Week - MSN

Oct 18, 2024
pulisher
Oct 18, 2024

Amylyx shares reiterate Buy rating on trial data - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

Amylyx shares reiterate Buy rating on trial data By Investing.com - Investing.com UK

Oct 18, 2024
pulisher
Oct 18, 2024

Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

H.C. Wainwright maintains Buy rating on Amylyx shares on trial data - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

H.C. Wainwright maintains Buy rating on Amylyx shares on trial data By Investing.com - Investing.com UK

Oct 18, 2024
pulisher
Oct 18, 2024

Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial - Clinical Trials Arena

Oct 18, 2024
pulisher
Oct 18, 2024

PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

Leerink maintains Market Perform rating on Amylyx stock on new data - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

Leerink maintains Market Perform rating on Amylyx stock on new data By Investing.com - Investing.com South Africa

Oct 18, 2024
pulisher
Oct 17, 2024

Amylyx reports positive trial results for Wolfram syndrome treatment - Investing.com India

Oct 17, 2024
pulisher
Oct 17, 2024

Amylyx reports positive trial results for Wolfram syndrome treatment By Investing.com - Investing.com South Africa

Oct 17, 2024
pulisher
Oct 17, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - StockTitan

Oct 17, 2024
pulisher
Oct 15, 2024

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - BioSpace

Oct 15, 2024
pulisher
Oct 15, 2024

Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR

Oct 15, 2024

Amylyx Pharmaceuticals Inc (AMLX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
大文字化:     |  ボリューム (24 時間):